WO2004112786A3 - Gaboxadol for treating depression and other affective disorders - Google Patents

Gaboxadol for treating depression and other affective disorders Download PDF

Info

Publication number
WO2004112786A3
WO2004112786A3 PCT/DK2004/000459 DK2004000459W WO2004112786A3 WO 2004112786 A3 WO2004112786 A3 WO 2004112786A3 DK 2004000459 W DK2004000459 W DK 2004000459W WO 2004112786 A3 WO2004112786 A3 WO 2004112786A3
Authority
WO
WIPO (PCT)
Prior art keywords
gaboxadol
treating depression
affective disorders
pharmaceutical composition
relates
Prior art date
Application number
PCT/DK2004/000459
Other languages
French (fr)
Other versions
WO2004112786A2 (en
Inventor
Connie Sanchez
Bjarke Ebert
Original Assignee
Lundbeck & Co As H
Connie Sanchez
Bjarke Ebert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2006515735A priority Critical patent/JP2007508236A/en
Priority to EA200600101A priority patent/EA200600101A1/en
Priority to MXPA05013016A priority patent/MXPA05013016A/en
Priority to MEP-2008-19A priority patent/ME00030B/en
Priority to PL04738956T priority patent/PL1641456T3/en
Priority to AT04738956T priority patent/ATE459353T1/en
Priority to NZ543586A priority patent/NZ543586A/en
Priority to AU2004248890A priority patent/AU2004248890A1/en
Priority to DK04738956.4T priority patent/DK1641456T3/en
Priority to DE602004025808T priority patent/DE602004025808D1/en
Priority to MEP-19/08A priority patent/MEP1908A/en
Priority to YUP-2005/0911A priority patent/RS20050911A/en
Application filed by Lundbeck & Co As H, Connie Sanchez, Bjarke Ebert filed Critical Lundbeck & Co As H
Priority to BRPI0410857-4A priority patent/BRPI0410857A/en
Priority to SI200431414T priority patent/SI1641456T1/en
Priority to EP04738956A priority patent/EP1641456B1/en
Priority to CA002529805A priority patent/CA2529805A1/en
Priority to US11/020,632 priority patent/US20050234093A1/en
Publication of WO2004112786A2 publication Critical patent/WO2004112786A2/en
Publication of WO2004112786A3 publication Critical patent/WO2004112786A3/en
Priority to IS8138A priority patent/IS8138A/en
Priority to IL172631A priority patent/IL172631A0/en
Priority to NO20060229A priority patent/NO20060229L/en
Priority to US12/389,764 priority patent/US20090203731A1/en
Priority to IL202106A priority patent/IL202106A0/en
Priority to HR20100276T priority patent/HRP20100276T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
PCT/DK2004/000459 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders WO2004112786A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
BRPI0410857-4A BRPI0410857A (en) 2003-06-25 2004-06-25 method for treating depression, use of gaboxadol, and pharmaceutical composition
EA200600101A EA200600101A1 (en) 2003-06-25 2004-06-25 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS
SI200431414T SI1641456T1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
PL04738956T PL1641456T3 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
AT04738956T ATE459353T1 (en) 2003-06-25 2004-06-25 GABOXADOL USED TO TREAT DEPRESSION AND OTHER AFFECTIVE DISORDERS
NZ543586A NZ543586A (en) 2003-06-25 2004-06-25 Gaboxadol4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol or THIP in monotherapy for treating depression and other affective disorders
AU2004248890A AU2004248890A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
DK04738956.4T DK1641456T3 (en) 2003-06-25 2004-06-25 Gaboxadol for the treatment of depression and other affective disorders
DE602004025808T DE602004025808D1 (en) 2003-06-25 2004-06-25 GABOXADOL FOR THE TREATMENT OF DEPRESSIONS AND OTHER AFFECTIVE DISORDERS
MEP-19/08A MEP1908A (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
YUP-2005/0911A RS20050911A (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
JP2006515735A JP2007508236A (en) 2003-06-25 2004-06-25 How to treat depression and other affective disorders
MXPA05013016A MXPA05013016A (en) 2003-06-25 2004-06-25 Aboxadol for treating depression and other affective disorders.
MEP-2008-19A ME00030B (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
EP04738956A EP1641456B1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
CA002529805A CA2529805A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
US11/020,632 US20050234093A1 (en) 2003-06-25 2004-12-22 Treatment of depression and other affective disorders
IS8138A IS8138A (en) 2003-06-25 2005-11-21 Gaboxadol for the treatment of depression and other psychiatric disorders
IL172631A IL172631A0 (en) 2003-06-25 2005-12-15 Gaboxadol for treating depression and other affective disorders
NO20060229A NO20060229L (en) 2003-06-25 2006-01-16 Gaboxadol for the treatment of depression and other affective disorders
US12/389,764 US20090203731A1 (en) 2003-06-25 2009-02-20 Treatment of depression and other affective disorders
IL202106A IL202106A0 (en) 2003-06-25 2009-11-12 Gaboxadol for treating depression and other affective disorders
HR20100276T HRP20100276T1 (en) 2003-06-25 2010-05-18 Gaboxadol for treating depression and other affective disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48301903P 2003-06-25 2003-06-25
US60/483,019 2003-06-25
DKPA200300956 2003-06-25
DKPA200300956 2003-06-25
US53512304P 2004-01-07 2004-01-07
US60/535,123 2004-01-07
DKPA200400016 2004-01-07
DKPA200400016 2004-01-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/020,632 Continuation-In-Part US20050234093A1 (en) 2003-06-25 2004-12-22 Treatment of depression and other affective disorders

Publications (2)

Publication Number Publication Date
WO2004112786A2 WO2004112786A2 (en) 2004-12-29
WO2004112786A3 true WO2004112786A3 (en) 2005-04-14

Family

ID=33545397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Country Status (17)

Country Link
EP (2) EP1641456B1 (en)
JP (1) JP2007508236A (en)
AT (1) ATE459353T1 (en)
AU (1) AU2004248890A1 (en)
BR (1) BRPI0410857A (en)
CY (1) CY1110046T1 (en)
DE (1) DE602004025808D1 (en)
DK (1) DK1641456T3 (en)
ES (1) ES2341004T3 (en)
HR (1) HRP20100276T1 (en)
IL (2) IL172631A0 (en)
MX (1) MXPA05013016A (en)
NZ (1) NZ543586A (en)
PL (1) PL1641456T3 (en)
PT (1) PT1641456E (en)
SI (1) SI1641456T1 (en)
WO (1) WO2004112786A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ATE454140T1 (en) 2004-02-18 2010-01-15 Sepracor Inc DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVES TO IMPROVE SLEEP QUALITY
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc Polymorphic forms of a gabaa agonist
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
TW200920358A (en) * 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP2012501301A (en) * 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット Pharmaceutical composition comprising gaboxadol and PAT1 inhibitor or OAT inhibitor
PT3274331T (en) 2015-03-24 2020-04-02 H Lundbeck As Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
MX2019005779A (en) * 2016-11-22 2019-08-22 Ovid Therapeutics Inc Methods of treating developmental disorders and/or seizure disorders with flupirtine.
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CN112601524A (en) * 2018-04-06 2021-04-02 奥维德医疗公司 Use of gaboxadol for treating substance use disorders
KR20210062662A (en) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. Use of Gaboksadol for the treatment of Tourette's syndrome, ticks and stuttering
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2021005994A (en) * 2018-11-21 2021-09-14 Certego Therapeutics Inc Combination of gaboxadol and lithium for the treatment of psychiatric disorders.
AU2019405489A1 (en) 2018-12-17 2021-06-10 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
KR20220114572A (en) 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. Gaboxadol for Therapeutic Treatment of 1p36 Deletion Syndrome
TW202208373A (en) 2020-05-20 2022-03-01 美商瑟泰戈治療學股份有限公司 Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254668A2 (en) * 2001-05-01 2002-11-06 Pfizer Products Inc. Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (en) 1977-06-20 1978-12-21 Krogsgaard Larsen P CYCLIC AMINO ACIDS
DE19525598C2 (en) 1995-07-13 1997-09-25 Max Planck Gesellschaft sleeping pills
AR031473A1 (en) * 2000-11-20 2003-09-24 Lundbeck & Co As H GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY
WO2002094225A1 (en) 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254668A2 (en) * 2001-05-01 2002-11-06 Pfizer Products Inc. Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN A V ET AL: "Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist.", PHARMACEUTISCH WEEKBLAD. SCIENTIFIC EDITION. 22 OCT 1982, vol. 4, no. 5, 22 October 1982 (1982-10-22), pages 145 - 153, XP008035614, ISSN: 0167-6555 *

Also Published As

Publication number Publication date
PL1641456T3 (en) 2010-08-31
CY1110046T1 (en) 2015-01-14
IL202106A0 (en) 2010-06-16
EP1641456B1 (en) 2010-03-03
EP1641456A2 (en) 2006-04-05
BRPI0410857A (en) 2006-07-04
SI1641456T1 (en) 2010-06-30
PT1641456E (en) 2010-06-01
HRP20100276T1 (en) 2010-06-30
ES2341004T3 (en) 2010-06-14
DK1641456T3 (en) 2010-06-21
IL172631A0 (en) 2006-04-10
ATE459353T1 (en) 2010-03-15
DE602004025808D1 (en) 2010-04-15
WO2004112786A2 (en) 2004-12-29
EP2145620A2 (en) 2010-01-20
JP2007508236A (en) 2007-04-05
MXPA05013016A (en) 2006-03-02
AU2004248890A1 (en) 2004-12-29
NZ543586A (en) 2009-07-31
EP2145620A3 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
IL172631A0 (en) Gaboxadol for treating depression and other affective disorders
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
EP2559694A3 (en) Azaindoles useful as inhibitors of Janus kinases
WO2006002097A3 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2006056695A8 (en) Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof
CL2008003231A1 (en) Substituted 1,3-dihydro-5-isobenzofurancarbonitrile derivative compounds, selective serotonin reuptake inhibitors; pharmaceutical composition; preparation procedure; Useful in the treatment and / or prevention of premature ejaculation.
WO2006087629A3 (en) Rapidly disintegrating composition of olanzapine
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
UA90656C2 (en) Gaboxadol for treating depression
MEP1908A (en) Gaboxadol for treating depression and other affective disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0911

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 11020632

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 543586

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/09356

Country of ref document: ZA

Ref document number: 200509356

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12005502115

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013016

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004738956

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004248890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 172631

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2529805

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006515735

Country of ref document: JP

Ref document number: 05129157

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020057024823

Country of ref document: KR

Ref document number: 20048175886

Country of ref document: CN

Ref document number: 3506/CHENP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004248890

Country of ref document: AU

Date of ref document: 20040625

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004248890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200600117

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200600101

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020057024823

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004738956

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410857

Country of ref document: BR